A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

Clinical trial NCT06032546 · TERMINATED

Trial details

NCT number: NCT06032546
Sponsor: AbbVie
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Human Immuno-deficiency Virus (HIV) Disease

Start date: 2023-10-12
Primary completion: 2025-09-22
Enrollment: 163

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.